Open-Angle Glaucoma (OAG) Market Report 2026

Open-Angle Glaucoma (OAG) Market Overview

• Open-Angle Glaucoma (OAG) market size has reached to $6.53 billion in 2025 • Expected to grow to $8.86 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Growing Awareness Of Eye Illnesses Drives Growth In The Market • Market Trend: Innovative Devices Revolutionize Glaucoma Treatment With Minimally Invasive Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Open-Angle Glaucoma (OAG) Market?

Open-angle glaucoma (OAG) is a chronic, progressive eye condition characterized by the gradual clogging of the drainage canals in the eye, leading to increased intraocular pressure that damages the optic nerve, often without noticeable symptoms until significant vision loss occurs. Its treatment aims to lower intraocular pressure, thereby preventing optic nerve damage and preserving vision through medications, laser procedures, or surgical interventions. The main disease types in open-angle glaucoma (OAG) are open angle glaucoma, angle closure glaucoma, and others. Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure leading to gradual optic nerve damage and potential vision loss, often without early symptoms. The drug classes used in the treatment are prostaglandin analogs, beta blockers, adrenergic agonists, carbonic anhydrase inhibitors, and others. The end users include hospitals, homecare, specialty clinics, and others. It is distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Open-Angle Glaucoma (OAG) Market Growth Forecast?

The open-angle glaucoma (oag) market size is expected to see strong growth in the next few years. It will grow to $8.86 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising demand for accessible online therapy, increasing adoption of mobile and web-based counseling tools, growing integration of ai-powered mental wellness solutions, rising use of hybrid therapy models combining individual and group sessions, expansion of online therapy offerings in commercial and residential segments. Major trends in the forecast period include rising adoption of prostaglandin analog drugs, increasing use of minimally invasive glaucoma surgeries, growing awareness about early diagnosis and screening, rising teleophthalmology consultations for oag management, increasing development of combination drug therapies.

Global Open-Angle Glaucoma (OAG) Market Segmentation

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types 2) By Drug Class: Prostaglandin Analog, Beta Blockers, Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Other Drug Classes 3) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users 4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy Subsegments: 1) By Open Angle Glaucoma (OAG): Primary Open-Angle Glaucoma (POAG), Secondary Open-Angle Glaucoma 2) By Angle Closure Glaucoma: Acute Angle-Closure Glaucoma, Chronic Angle-Closure Glaucoma 3) By Other Disease Types: Normal-Tension Glaucoma, Congenital Glaucoma, Secondary Glaucoma

What Is The Driver Of The Open-Angle Glaucoma (OAG) Market?

The growing awareness of eye illnesses is expected to propel the growth of the open-angle glaucoma (OAG) market going forward. Eye illnesses encompass medical conditions impacting the structure, function, or vision of the eyes, ranging from minor concerns such as dry eye to serious diseases such as glaucoma and macular degeneration. Their prevalence is rising due to aging populations, prolonged screen exposure, increasing diabetes cases, environmental pollution, and lifestyle habits that strain eye health. Open-angle glaucoma (OAG), a leading cause of blindness, especially among older adults, underscores the critical need for routine eye exams, early diagnosis, and proactive treatment to safeguard against irreversible vision loss. For instance, in October 2023, according to the Royal National Institute of Blind People (RNIB), a UK-based sight loss charity, eye care outpatient appointments in the UK exceeded eight million in 2021/22, making it the most in-demand specialty. Additionally, the number of individuals with sight loss, currently surpassing two million, is projected to double to over four million by 2050. Therefore, the growing awareness of eye illnesses is driving growth in the open-angle glaucoma (OAG) industry.

Key Players In The Global Open-Angle Glaucoma (OAG) Market

Major companies operating in the open-angle glaucoma (oag) market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Alcon Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Santen Pharmaceuticals, Théa Pharma, Glaukos Corporation, Quantel Medical, EyePoint Pharmaceuticals Inc., iSTAR Medical, Nicox Ophthalmics, Visus Therapeutics, Inotek Pharmaceuticals, Hoya Corporation, Boston Scientific, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, Topcon Corporation, Nidek Co. Ltd., Heidelberg Engineering GmbH, New World Medical Inc.

Global Open-Angle Glaucoma (OAG) Market Trends and Insights

Major companies operating in the open-angle glaucoma (OAG) market are prioritizing the development of innovative solutions, such as minimally invasive glaucoma devices (MIGDs), to provide advanced and less invasive alternatives for managing primary open-angle glaucoma while reducing reliance on traditional treatments. A minimally invasive glaucoma device (MIGD) refers to a range of surgical implants and techniques designed to lower intraocular pressure in glaucoma patients through small incisions and minimal disruption of ocular tissues. For instance, in December 2023, iSTAR Medical, a Belgium-based medtech company, launched MINIject in the Netherlands. This bio-integrating treatment for primary open-angle glaucoma utilizes a unique porous STAR material to enhance fluid outflow and reduce IOP. By decreasing dependency on conventional therapies, MINIject represents a significant breakthrough in glaucoma care, offering a safer and more effective management option for this leading cause of permanent blindness.

What Are Latest Mergers And Acquisitions In The Open-Angle Glaucoma (OAG) Market?

In July 2024, Alcon Inc., a Switzerland-based ophthalmology company, acquired BELKIN Vision Ltd. for $81 million. This acquisition aims to enhance Alcon's glaucoma portfolio by introducing the direct selective laser trabeculoplasty (DSLT) device, a cutting-edge first-line laser treatment for managing open-angle glaucoma. The move aligns with Alcon's strategy to globally expand access to innovative and minimally invasive glaucoma treatments. BELKIN Vision Ltd. is an Israel-based medical device company providing devices for open-angle glaucoma treatments.

Regional Outlook

North America was the largest region in the open-angle glaucoma (OAG) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Open-Angle Glaucoma (OAG) Market?

The open-angle glaucoma (OAG) market consists of revenues earned by entities by providing services such as optometric services, surgical interventions, medication management, and patient education and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The open-angle glaucoma (OAG) market also includes sales of tonometers, visual field analyzers, and lubricating eye drops. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Open-Angle Glaucoma (OAG) Market Report 2026?

The open-angle glaucoma (oag) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the open-angle glaucoma (oag) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.